Periscope Capital’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Periscope Capital’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-776,797	Closed	-$7.85M	–	909
2022 Q4	$7.85M	Sell	776,797 -66,426	-8%	-$664K	0.34%	89
2022 Q3	$8.36M	Buy	843,223 +336,744	+66%	+$3.32M	0.24%	146
2022 Q2	$4.96M	Hold	506,479	–	–	0.13%	311
2022 Q1	$4.95M	Hold	506,479	–	–	0.13%	322
2021 Q4	$4.91M	Buy	506,479 +464,400	+1,104%	+$4.52M	0.13%	308
2021 Q3	$409K	Hold	42,079	–	–	0.01%	592
2021 Q2	$409K	Buy	+42,079	New	+$413K	0.01%	546

Periscope Capital's EBAC Position: Q1 2023 in Review

Periscope Capital sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 776,797 shares — an estimated $7.85M sold.

Periscope Capital first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $8.36M in Q3 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Periscope Capital reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Periscope Capital sold 776,797 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $7.85M.
Periscope Capital first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Periscope Capital's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $8.36M in Q3 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Periscope Capital's 13F filing for Q1 2023, filed 12 May 2023.